Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

802162

registered interest
date	06/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Radiology
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the NHS’ capacity to deliver 24-hour interventional radiology (image-guided surgery) services in each region.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	117849
answer	answer is ministerial correction date of answer 11/12/2017 answer text <p>The seven day services self-assessment survey completed by trusts in March 2017 included information on the availability of clinical interventions, including interventional radiology (IR), on a seven day basis for patients admitted to hospital in an emergency. The data showed that <ins class="ministerial">72.30%</ins><del class="ministerial">73.65%</del> of hospital trusts who responded to this survey (<del class="ministerial">109 </del> <ins class="ministerial">107</ins>out of 148 trusts) stated that IR was available for these patients seven days a week.</p><p> </p><p>Information on the twice yearly collection is available on the NHS England website at:</p><p><a href="https://www.england.nhs.uk/seven-day-hospital-services/progress" target="_blank">https://www.england.nhs.uk/seven-day-hospital-services/progress</a></p><p>National Health Service regions have access to this report and will be able to consider any variation.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 11/12/2017 17:57:45 question first ministerially corrected 26/01/2018 14:08:27 answering member 1542 label Biography information for Philip Dunne previous answer version 28792 answering member constituency Ludlow answering member printed Mr Philip Dunne answering member 1542 label Biography information for Philip Dunne
tabling member	298 label Biography information for Steve McCabe

802408

registered interest
date	06/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 5 December (HL3500), whether they will place a copy of the systematic review of serious adverse reactions following HPV vaccines, commissioned by the World Health Organisation, in the Library of the House.
tabling member printed	The Countess of Mar
uin	HL3941
answer	answer is ministerial correction date of answer 20/12/2017 answer text <p>The Global Advisory Committee on Vaccine Safety (GACVS) provides independent, authoritative, scientific advice to the World Health Organization (WHO) on vaccine safety issues. The GACVS public summary report dated 14 July 2017 states that it was presented with a draft of a systematic review of serious adverse events following human papillomavirus (HPV) vaccines that had been commissioned by WHO and summarises its findings. This found no difference in rates of selected serious adverse events between those exposed and unexposed to HPV vaccine. A copy of the systematic review, <em>Serious adverse events associated with HPV vaccination</em>, is attached.</p> answering member printed Lord O'Shaughnessy question first answered 20/12/2017 16:54:10 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name HPV vaccination safety report _AHTA dec17.pdf title Serious adverse events associated with HPV
tabling member	1861 label Biography information for The Countess of Mar

802409

registered interest
date	06/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mefloquine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answers by Lord O'Shaughnessy on 5 December (HL3532) and 27 November (HL3227), whether they have seen the unclassified order of the US Surgeon General’s Office of the Army Special Command of 13 September 2013; whether there is any difference between the drug of the same name administered to US troops and that issued to British troops; and why it is necessary to demonstrate that the neurological damage caused by the administration of mefloquine is permanent before acknowledging the persistence of the neurotoxic effects of the drug.
tabling member printed	The Countess of Mar
uin	HL3942
answer	answer is ministerial correction date of answer 19/12/2017 answer text <p>We have considered this order.</p><p>There is no difference in the anti-malarial drug Mefloquine (under the brand name Lariam) currently provided to the United Kingdom and United States armed forces.</p><p>Mefloquine is effective in the prevention and treatment of malaria. Approved by the Medicines and Health products Regulatory Agency, the current product information states that neuropsychiatric adverse reactions may occur during treatment and includes warnings and precautions to minimise these risks. Some of these reactions may persist, but it has not been established whether these are permanent.</p><p>Mefloquine continues to be recommended as a safe and effective form of malaria prevention by the Advisory Committee on Malaria Prevention, the World Health Organization and other respected organisations who take account of the body of global evidence.</p> answering member printed Lord O'Shaughnessy question first answered 19/12/2017 14:14:06 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1861 label Biography information for The Countess of Mar